By Katherine Hamilton
BioAge Labs shares rose Wednesday after it said it entered into a research collaboration with the Swiss biopharmaceutical company Novartis, which could earn BioAge up to $550 million.
Shares climbed 14% to $4.67, helping to regain some of the 76% loss BioAge experienced on Dec. 6 after it said it was discontinuing a phase-two trial for its obesity treatment.
The Richmond, Calif.-based biopharmaceutical company will collaborate on a multi-year research project with Novartis investigating what drives aging-related diseases and the role of physical exercise in longevity. It combines BioAge's human longevity datasets with Novartis's specialty in exercise biology, BioAge said.
Under the terms of the agreement, BioAge will receive upfront research funding and payments of up to $20 million, and up to $530 million in future research, development and commercial milestones. BioAge and Novartis both have the right to advance novel targets discovered during the collaboration.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 18, 2024 10:21 ET (15:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。